For Q1 FY2026 ended March 31, 2026, Vaxcyte reported no revenue and a net loss of $320.6 million, a 127.8% increase from the prior year. Operating loss was $345.9 million, up 91.3% year-over-year. Diluted EPS was -$2.30, compared to -$1.04 in Q1 FY2025. Cash and cash equivalents totaled $260.8 million, and total equity was $3.0 billion.
•No revenue reported for Q1 FY2026.
•Net loss widened to $320.6 million from $140.8 million in Q1 FY2025.
•Operating loss increased to $345.9 million from $180.8 million year-over-year.
•Diluted EPS was -$2.30, compared to -$1.04 in the prior year period.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Vaxcyte, Inc., a clinical-stage vaccine innovation company develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. It also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children.
Its portfolio also includes VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus, VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria, and VAX-XL, a third-generation pneumococcal conjugate vaccine. Incorporated in 2013 and headquartered in San Carlos, California, Vaxcyte was formerly known as SutroVax, Inc. before rebranding in May 2020.
Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for preventing invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent PCV for adults and children, and has a pipeline including VAX-A1 for Group A Streptococcus, VAX-PG for periodontitis, VAX-GI for dysentery and shigellosis, and VAX-XL, a third-generation pneumococcal conjugate vaccine. Vaxcyte was formerly known as SutroVax, Inc. before rebranding in May 2020.
Where is Vaxcyte (PCVX) listed and what currency does it trade in?
Vaxcyte, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PCVX. Its shares are traded in United States Dollars (USD). The company is headquartered in San Carlos, California, and operates primarily in the United States. As a Nasdaq-listed company, it is subject to US securities regulations and reporting requirements.
What sector and industry does Vaxcyte (PCVX) belong to?
Vaxcyte operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of vaccines using innovative technologies, such as carrier-sparing conjugate vaccines. Its work is primarily in the prevention of bacterial infectious diseases, including pneumococcal disease, Group A Streptococcus, periodontitis, and shigellosis. The company's clinical-stage status means its products are still undergoing trials and have not yet received regulatory approval for commercial use.
Where is Vaxcyte (PCVX) headquartered and what markets does it serve?
Vaxcyte, Inc. is headquartered in San Carlos, California, United States. The company serves the US market primarily, as indicated by its country and region designation. Its vaccine candidates target diseases that affect global populations, but as a clinical-stage company, it has not yet commercialized any products. The company was incorporated in 2013 and was originally named SutroVax, Inc. before rebranding in May 2020. Its research and development activities are centered in the US, and it aims to address unmet medical needs in infectious diseases.
What are the main vaccine candidates in Vaxcyte's (PCVX) pipeline?
Vaxcyte's pipeline includes several vaccine candidates at various stages of development. The lead candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for preventing invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent PCV for adults and children. Additionally, its portfolio includes VAX-A1, a novel conjugate vaccine candidate for Group A Streptococcus; VAX-PG, a novel protein vaccine targeting the keystone pathogen responsible for periodontitis; VAX-GI, a preclinical vaccine candidate for dysentery and shigellosis caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. All candidates are in clinical or preclinical stages.